Target safety assessment
Understanding your drug target is where successful drug discovery begins. Support your target identification, target evaluation and target derisking with TNO’s concise and customizable target evaluation reports. Our unique set of assessments and web-based target triaging platform TargetTri, can help to make informed decision making easy with transparent, knowledge-driven expert views on target efficacy, safety liabilities, and risk mitigation.
Target Profiling Services
With a track record of many years, TNO can help you understand the risks and benefits of target modulation in an early phase of drug development. With multidisciplinary teams, we extract, integrate and interpret target-related data and transform this information into a transparent, strategic document suitable for strategic decision making. Our routine services include Target Safety Assessments (TSA) and Target Efficacy Assessments (TEA). In addition, we are developing the web-based target triaging platform TargetTri in collaboration with the pharmaceutical/biotech industry.
Target Safety Assessment
TSA combines cheminformatics, network biology, data- and text-mining to create a comprehensive report on the safety profile of a target. The TSAs are performed and authored by expert project toxicologists and support knowledge-driven decision making regarding target progression and risk mitigation strategies. To accommodate your needs, we offer a tiered approach in the detail level of our TSAs as well as fully customizable content. Our reports are delivered in either a PowerPoint or Word format.
A typical TSA contains:
- Executive summary with ranked safety risks
- Target characteristics
- Competitive intelligence
- Expression profile and biological function per organ system
- Human and animal genetic profiles
- (Pre)clinical safety information
- Identified risks per organ system
- Risk ranking
Target Efficacy Assessment
Our TEA helps you support the nomination of a novel drug target for a specific disease indication. The target is evaluated in the context of relevant molecular disease mechanisms and evidence either supporting or contradicting its therapeutic value is reported upon in a comprehensive PowerPoint document. Our TEA mirrors much of the TSA both in approach and content and is executed and authored by a multidisciplinary team of experts. Aspects specific to the TEA include the therapeutic rationale of the target, available medicinal chemistry tools and an executive summary highlighting the pros and cons of the target in view of its intended therapeutic application.
Would you rather interpret knowledge on target modulation yourself but are losing valuable time collecting the relevant data? If so, our web-based TargetTri platform for target triaging is for you. This intelligence platform is collaboratively developed with pharma partners and extracts target-centric data from public databases and literature on the fly. It among others captures information on diseases, genetic variants and therapeutics. Our proprietary ontologies and text-mining system furthermore ensures efficient extraction of meaningful protein-effect relationships in dynamic views that can be explored per organ system. Although still under development, we welcome interested parties to contact us.
Why TNO for target profiling?
- Multidisciplinary team of experts
- Proprietary IT platform for efficient big data handling/integration and text-mining
- Extensive track record and trusted partner of multiple pharmaceutical companies
- Flexible content and reporting structure for our target evaluations
- Relieve of your limited in-house resources
Want to find out more?
Let us know if you are interested in an example report, recent posters or a demonstration of TargetTri by sending an email to Simon Folkertsma.
Looking for another expert?View all experts
TNO helps accelerate drug development through insight
To find the most effective interventions for complex metabolic diseases, we must first understand the dynamics of disease onset and progression. Only then can key targets and optimal therapeutic windows for more effective treatment be defined. We spoke with Anita van den Hoek, Research Scientist for TNO Metabolic Health, about how TNO helps pharmaceutical companies accelerate drug development through better understanding of disease pathways.
TNO proves method for effective pediatric drug development
Safe and effective drug dosing for young children come with their own challenges. Up to the age of 18, a child’s metabolism can change significantly. And in the first two years of life, those ontogenic differences can be rapid and dramatic. TNO published its findings from the first drug disposition (mass balance/metabolite profiling) study to conclusively prove that microtracing with accelerator mass spectrometry (AMS) is an effective way to collect clinical data in these young patients. This AMS technology can also be the key to building up more data on drug interventions in pregnant and lactating mothers.
Functional microbiome analysis
TNO has a wide range of available tools to increase understanding of the impact and interaction of the microbiome on human health. Learn more.
PK Studies AMS
With TNO’s microtracer expertise, drug development becomes a streamlined and targeted process.
Advanced microtracer studies
A drug’s ADME and ADR's are often difficult to predict. At TNO we have developed in vitro and ex vivo platforms that can help to make this easier.